Loading...
Therapies targeting aggregated α-synuclein in Parkinson disease (PD) have been of great interest as a potential therapeutic and disease modifier. Cinpanemab is a human-derived N-terminal–directed monoclonal antibody that binds α-synuclein. Researchers performed a 52-week, multicenter, double-blind, phase 2 trial focused on 357 patients with early PD who were randomized 2:1:2:2 to receive placebo or cinpanemab doses of 250 mg, 1250 mg, or 3500 mg, delivered monthly. There was also an active-treatment, dose-blinded extension period for up to 112 weeks total. In 110 of 118 participants tested, aggregation-inducing α-synuclein was found in the spinal fluid. The primary outcome was the change from baseline in the Movement Disorder Society United…